In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


StemCells Finds White Knight In Microbot

Executive Summary

In May 2016, results from StemCell Inc.’s Phase II study of its only product still in development, a preparation of human neural stem cells for the treatment of chronic spinal cord injuries, suggested that there was little chance of the product ever becoming a commercial success. The company’s stock plummeted 80% overnight. Then, in August, when all appeared to be lost, StemCells announced that it was entering a strategic merger agreement with the Israeli company Microbot Medical Ltd., which researches and develops micro-robotic assisted medical technologies.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts